Magazine Article
| June 7, 2017

Genentech Masters Breakthrough Therapy Designation

Genentech has garnered 15 Breakthrough Therapy Designations for its medicines since 2013, which is more than any other company. Jeffrey Siegel, senior group medical director for Genentech, believes this success reflects the company’s focus on developing new approaches to address unmet medical needs.

It also makes him a bit of an expert in understanding the intricacies of the FDA program. Siegel was with the FDA for 14 years before joining Genentech and has devoted most of his career to facilitating the development of products to address unmet needs.